Advertisement


Tony Mok, MD, on NSCLC: Targeted Treatment Update

ESMO 2018 Congress

Advertisement

Tony Mok, MD, of the Chinese University of Hong Kong, discusses two important studies in non–small cell lung cancer: FLAURA, which looked at the first-line activity of osimertinib and the mechanisms of resistance; and ALESIA, which examined crizotinib dosing.  



Related Videos

Bladder Cancer
Immunotherapy

Ronald de Wit, MD, PhD, on Bladder Cancer: Results From KEYNOTE-057

Ronald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses phase II findings on the efficacy of pembrolizumab in bacillus Calmette-Guérin–unresponsive bladder cancer with high risk for disease progression.

Lung Cancer
Immunotherapy

Suresh S. Ramalingam, MD, on Lung Cancer: Research Highlights

Suresh S. Ramalingam, MD, of the Emory University School of Medicine, summarizes the top-line lung cancer results reported at this year’s ESMO Congress, including the role of targeted treatment for early stage NSCLC, combining immunotherapy for surgically resectable disease, and immunotherapy for small–cell lung cancer as well as unresectable NSCLC.

Issues in Oncology

Matti S. Aapro, MD, on Advanced Disease: Reducing Use of Futile Treatments

Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the challenges of avoiding futile treatments and the need to work with patients, integrate palliative care, and monitor toxicities.

Hepatobiliary Cancer

Eileen M. O’Reilly, MD, on Hepatobiliary Cancer: Multimodality Approaches

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest information on locoregional and systemic treatments of hepatocellular carcinoma as well as targeted therapy for biliary cancer.

Skin Cancer

Alexander M.M. Eggermont, MD, PhD, on Melanoma: Advances in Adjuvant Therapy

Alexander M.M. Eggermont, MD, PhD, of Gustave Roussy, discusses findings from recent adjuvant trials in high-risk melanoma, and what the NCCN Guidelines recommend in light of such data as results on dabrafenib plus trametinib vs anti–PD-1 treatments (nivolumab or pembrolizumab) and the new standard for wild-type disease.

Advertisement

Advertisement




Advertisement